PREVANCIA Trademark

Trademark Overview


On Friday, March 2, 2018, a trademark application was filed for PREVANCIA with the United States Patent and Trademark Office. The USPTO has given the PREVANCIA trademark a serial number of 87817929. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 21, 2022. This trademark is owned by Allergan Sales, LLC. The PREVANCIA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable...
prevancia

General Information


Serial Number87817929
Word MarkPREVANCIA
Filing DateFriday, March 2, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 21, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 24, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 9, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressIrvine, CA 92612

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Trademark Events


Event DateEvent Description
Tuesday, February 22, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 21, 2022ABANDONMENT - NO USE STATEMENT FILED
Wednesday, July 21, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 20, 2021EXTENSION 5 GRANTED
Monday, July 12, 2021EXTENSION 5 FILED
Monday, July 19, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, July 12, 2021TEAS EXTENSION RECEIVED
Saturday, January 9, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 7, 2021EXTENSION 4 GRANTED
Thursday, January 7, 2021EXTENSION 4 FILED
Thursday, January 7, 2021TEAS EXTENSION RECEIVED
Tuesday, June 30, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 26, 2020EXTENSION 3 GRANTED
Friday, June 26, 2020EXTENSION 3 FILED
Friday, June 26, 2020TEAS EXTENSION RECEIVED
Saturday, January 11, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 9, 2020EXTENSION 2 GRANTED
Thursday, January 9, 2020EXTENSION 2 FILED
Thursday, January 9, 2020TEAS EXTENSION RECEIVED
Tuesday, June 18, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 14, 2019EXTENSION 1 GRANTED
Friday, June 14, 2019EXTENSION 1 FILED
Friday, June 14, 2019TEAS EXTENSION RECEIVED
Tuesday, January 15, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sunday, December 2, 2018EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Wednesday, October 31, 2018CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Monday, October 22, 2018ASSIGNED TO PETITION STAFF
Tuesday, September 18, 2018TEAS POST PUBLICATION AMENDMENT RECEIVED
Wednesday, August 22, 2018EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, July 24, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 24, 2018PUBLISHED FOR OPPOSITION
Wednesday, July 4, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, June 14, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, June 14, 2018ASSIGNED TO EXAMINER
Friday, March 9, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, March 6, 2018NEW APPLICATION ENTERED IN TRAM